Federal Register / Vol. 74, No. 10 / Thursday, January 15, 2009 / Notices 2619 

Clinical Services, Inc. to ensure that the 

company’s registration is consistent 

with the public interest. The 

investigation has included inspection 

and testing of the company’s physical 

security systems, verification of the 

company’s compliance with state and 

local laws, and a review of the 

company’s background and history. 

Therefore, pursuant to 21 U.S.C. 952(a) 

and 958(a), and in accordance with 21 

CFR § 1301.34, the above named 

company is granted registration as an 

importer of the basic class of controlled 

substance listed. 

Dated: January 9, 2009. 

Joseph T. Rannazzisi, 

Deputy Assistant Administrator, Office of 

Diversion Control, Drug Enforcement 

Administration. 

[FR Doc. E9–731 Filed 1–14–09; 8:45 am] 

BILLING CODE 4410–09–P 

DEPARTMENT OF JUSTICE 

Drug Enforcement Administration 

Importer of Controlled Substances; 

Notice of Registration 

By Notice dated October 6, 2008, and 

published in the Federal Register on 

October 14, 2008, (73 FR 60719), 

Hospira Inc., 1776 North Centennial 

Drive, McPherson, Kansas 67460–1247, 

made application by renewal to the 

Drug Enforcement Administration 

(DEA) to be registered as an importer of 

Remifentanil (9739), a basic class of 

controlled substance listed in schedule 

II. 

The company plans to import 

Remifentanil for use in dosage form 

manufacturing. 

No comments or objections have been 

received. DEA has considered the 

factors in 21 U.S.C. 823(a) and 952(a) 

and determined that the registration of 

Hospira, Inc. to import the basic class of 

controlled substance is consistent with 

the public interest, and with United 

States obligations under international 

treaties, conventions, or protocols in 

effect on May 1, 1971, at this time. DEA 

has investigated Hospira, Inc. to ensure 

that the company’s registration is 

consistent with the public interest. The 

investigation has included inspection 

and testing of the company’s physical 

security systems, verification of the 

company’s compliance with state and 

local laws, and a review of the 

company’s background and history. 

Therefore, pursuant to 21 U.S.C. 952(a) 

and 958(a), and in accordance with 21 

CFR 1301.34, the above named company 

is granted registration as an importer of 

the basic class of controlled substance 

listed. 

Dated: January 9, 2009. 

Joseph T. Rannazzisi, 

Deputy Assistant Administrator, Office of 

Diversion Control, Drug Enforcement 

Administration. 

[FR Doc. E9–732 Filed 1–14–09; 8:45 am] 

BILLING CODE 4410–09–P 

DEPARTMENT OF JUSTICE 

Drug Enforcement Administration 

Importer of Controlled Substances; 

Notice of Registration 

By Notice dated October 2, 2008, and 

published in the Federal Register on 

October 8, 2008, (73 FR 58979), Clinical 

Supplies Management, Inc., 342 42nd. 

Street, South Fargo, North Dakota 

58103, made application by renewal to 

the Drug Enforcement Administration 

(DEA) to be registered as an importer of 

Sufentanil (9740), a basic class of 

controlled substance listed in schedule 

II. 

The company plans to import the 

listed controlled substance for clinical 

trials, research, and analytical purposes. 

No comments or objections have been 

received. DEA has considered the 

factors in 21 U.S.C. 823(a) and 952(a) 

and determined that the registration of 

Clinical Supplies Management, Inc. to 

import the basic class of controlled 

substance is consistent with the public 

interest, and with United States 

obligations under international treaties, 

conventions, or protocols in effect on 

May 1, 1971, at this time. DEA has 

investigated Clinical Supplies 

Management, Inc. to ensure that the 

company’s registration is consistent 

with the public interest. The 

investigation has included inspection 

and testing of the company’s physical 

security systems, verification of the 

company’s compliance with state and 

local laws, and a review of the 

company’s background and history. 

Therefore, pursuant to 21 U.S.C. 952(a) 

and 958(a), and in accordance with 21 

CFR 1301.34, the above named company 

is granted registration as an importer of 

the basic class of controlled substance 

listed. 

Dated: January 9, 2009. 

Joseph T. Rannazzisi, 

Deputy Assistant Administrator, Office of 

Diversion Control, Drug Enforcement 

Administration. 

[FR Doc. E9–733 Filed 1–14–09; 8:45 am] 

BILLING CODE 4410–09–P 

DEPARTMENT OF JUSTICE 

Drug Enforcement Administration 

Manufacturer of Controlled 

Substances; Notice of Registration 

By Notice dated October 2, 2008 and 

published in the Federal Register on 

October 8, 2008, (73 FR 58979), National 

Center for Natural Products Research— 

NIDA MProject, University of 

Mississippi, 135 Coy Waller Complex, 

University, Mississippi 38677, made 

application by renewal to the Drug 

Enforcement Administration (DEA) to 

be registered as a bulk manufacturer of 

the basic classes of controlled 

substances listed in schedule I: 

Drug Schedule 

Marihuana (7360) ......................... I 

Tetrahydrocannabinols (7370) ...... I 

The company plans to cultivate 

marihuana for the National Institute on 

Drug Abuse for research approved by 

the Department of Health and Human 

Services. 

No comments or objections have been 

received. DEA has considered the 

factors in 21 U.S.C. 823(a) and 

determined that the registration of 

National Center for Natural Products 

Research—NIDA MProject to 

manufacture the listed basic classes of 

controlled substances is consistent with 

the public interest at this time. DEA has 

investigated National Center for Natural 

Products Research—NIDA MProject to 

ensure that the company’s registration is 

consistent with the public interest. The 

investigation has included inspection 

and testing of the company’s physical 

security systems, verification of the 

company’s compliance with state and 

local laws, and a review of the 

company’s background and history. 

Therefore, pursuant to 21 U.S.C. 823, 

and in accordance with 21 CFR 1301.33, 

the above named company is granted 

registration as a bulk manufacturer of 

the basic classes of controlled 

substances listed. 

Dated: January 9, 2009. 

Joseph T. Rannazzisi, 

Deputy Assistant Administrator, Office of 

Diversion Control, Drug Enforcement 

Administration. 

[FR Doc. E9–719 Filed 1–14–09; 8:45 am] 

BILLING CODE 4410–09–P 


jlentini on PROD1PC65 with NOTICES